Cytos Biotechnology AG, Immunodrugs, Zurich, Switzerland.
Curr Opin Immunol. 2010 Jun;22(3):391-6. doi: 10.1016/j.coi.2010.02.009. Epub 2010 Mar 24.
Chronic non-communicable diseases (NCDs) are increasingly recognized as the major cause of morbidity and mortality worldwide. Effective, affordable and broadly accessible medicines for their treatment are much sought after. Therapeutic B-cell vaccines aim at inducing neutralizing auto-reactive antibodies against important mediators of such diseases. Numerous animal models have demonstrated that active immunotherapy can induce disease-modifying levels of auto-antibodies. Recent findings from clinical trials have indicated that self-reactive antibodies can also be readily induced in humans; therapeutic efficacy, however, has not always been achieved. To date, clinical experience with vaccines against self-molecules is limited. Choice of the right target, proper vaccine design, optimal vaccine dose and regimen remain the major challenges to achieve clinical efficacy and safety for this novel class of biotherapeutics.
慢性非传染性疾病（NCDs）日益被认为是全球发病率和死亡率的主要原因。人们迫切需要有效、负担得起且广泛可获得的治疗药物。治疗性 B 细胞疫苗旨在诱导针对这些疾病重要介质的中和自身反应性抗体。许多动物模型已经证明，主动免疫疗法可以诱导疾病修饰水平的自身抗体。最近的临床试验结果表明，自身反应性抗体也可以在人类中轻易诱导；然而，治疗效果并不总是能够实现。迄今为止，针对自身分子的疫苗的临床经验有限。选择正确的靶标、适当的疫苗设计、最佳的疫苗剂量和方案仍然是实现这一新类生物治疗药物的临床疗效和安全性的主要挑战。
